StockNews.AI
SEER
StockNews.AI
4 hrs

Seer Reports Third Quarter 2025 Financial Results

1. SEER generated $4.1 million revenue in Q3 2025, a 2% increase. 2. Record number of third-party publications validates Proteograph's performance. 3. They ended Q3 with $251.2 million in cash and investments. 4. Operating expenses decreased by 18% year-over-year. 5. Full year 2025 revenue guidance set between $17 million and $18 million.

11m saved
Insight
Article

FAQ

Why Bullish?

The revenue growth and strong demand for Proteograph ONE indicate business momentum. Historical examples show that financial improvement and increased adoption can lead to stock appreciation.

How important is it?

The financial results and strategic outlook are critical for evaluating SEER's market position and potential for growth. Strong revenue coupled with cash reserves suggests resilience and future investments.

Why Short Term?

Immediate revenue growth and costs improvements can positively affect investor sentiment. Similar past reports led to short-term price increases for SEER.

Related Companies

PTCTAXONCGEN
November 06, 2025 16:05 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $4.1 million for the third quarter of 2025Achieved a record quarter for third-party publications and preprints, with more than 60 total to dateEnded the quarter with approximately $251.2 million of cash, cash equivalents and investments “In Q3, we saw robust demand and utilization for our recently launched Proteograph ONE workflow, resulting in another strong quarter for instrument shipments. Notably, we have shipped nearly three times as many instruments in the first nine months of this year as we did in all of 2024,” said Omid Farokhzad, Chair and CEO of Seer. “We also saw a record number of third-party publications demonstrating the value of the Proteograph and further validating its performance across a range of applications. Together, these achievements highlight the growing adoption of our technology and reinforce our leadership in enabling deep, unbiased proteomics at scale. I’m proud of our team’s execution as we advance the reach and impact of the Proteograph Product Suite.” Third Quarter 2025 Financial Results Revenue was $4.1 million for the third quarter of 2025, a 2% increase from $4.0 million for the corresponding prior year period, primarily due to higher product sales and service revenue in the quarter. Product revenue for the third quarter of 2025 was $2.8 million and consisted of sales of Proteograph instruments and consumable kits. Service revenue was $1.2 million for the third quarter of 2025, including $300 thousand of related party revenue, and primarily consisted of revenue related to Seer Technology Access Center service projects. Other revenue was $152 thousand for the third quarter of 2025. Gross profit was $2.1 million and gross margin was 51% for the third quarter of 2025. Operating expenses were $21.5 million for the third quarter of 2025, including $3.5 million of stock-based compensation, a decrease of 18% compared to $26.3 million for the corresponding prior year period, including $6.1 million of stock-based compensation. The decrease in operating expenses was primarily driven by a reduction in stock-based compensation, business expenses, and allocated costs. Net loss was $18.2 million for the third quarter of 2025, compared to $21.3 million for the corresponding prior year period. Cash, cash equivalents and investments were approximately $251.2 million as of September 30, 2025. 2025 Guidance Seer continues to expect full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024. Webcast Information Seer will host a conference call to discuss the third quarter 2025 financial results on Thursday, November 6, 2025 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event. About Seer Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2025. ​These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact:Carrie Mendivilinvestor@seer.bio Media Contact:Patrick Schmidtpr@seer.bio SEER, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)(in thousands, except share and per share amounts) Three Months Ended September 30,  Nine Months Ended September 30,  2025  2024  2025  2024 Revenue:           Product$2,756  $2,915  $8,372  $6,344 Service 913   661   2,913   1,751 Related party 300   366   761   1,903 Other 152   90   331   172 Total revenue 4,121   4,032   12,377   10,170 Cost of revenue:           Product 1,327   1,510   3,868   3,202 Service 335   268   1,261   899 Related party 85   183   224   651 Other 264   133   742   388 Total cost of revenue 2,011   2,094   6,095   5,140 Gross profit 2,110   1,938   6,282   5,030 Operating expenses:           Research and development 10,797   12,967   34,132   37,966 Selling, general and administrative 10,659   13,296   32,757   43,677 Total operating expenses 21,456   26,263   66,889   81,643 Loss from operations (19,346)  (24,325)  (60,607)  (76,613)Other income (expense):           Interest income 2,765   4,082   8,974   13,101 Loss on equity method investment (1,419)  (861)  (4,835)  (861)Other expense (210)  (224)  (965)  (484)Total other income 1,136   2,997   3,174   11,756 Loss before provision for income taxes (18,210)  (21,328)  (57,433)  (64,857)Provision for income taxes 24   —   173   — Net loss$(18,234) $(21,328) $(57,606) $(64,857)Other comprehensive loss:           Unrealized gain on available-for-sale securities 124   1,415   295   981 Comprehensive loss$(18,110) $(19,913) $(57,311) $(63,876)Net loss per share attributable to Class A and Class B common stockholders, basic and diluted$(0.32) $(0.35) $(0.99) $(1.02)Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted 56,312,290   61,186,324   57,928,898   63,441,333                  SEER, INC.Condensed Consolidated Balance Sheets(Unaudited)(in thousands, except share and per share amounts)  September 30,2025  December 31,2024 ASSETS      Current assets:      Cash and cash equivalents $44,973  $40,753 Short-term investments  154,262   195,657 Accounts receivable, net  3,502   3,997 Related party receivables  300   379 Other receivables  1,355   1,853 Inventory  8,126   7,436 Prepaid expenses and other current assets  1,845   3,248 Total current assets  214,363   253,323 Long-term investments  51,950   63,103 Operating lease right-of-use assets  21,077   22,791 Property and equipment, net  15,474   18,575 Restricted cash  524   524 Other assets  5,220   8,281 Total assets $308,608  $366,597 LIABILITIES AND STOCKHOLDERS’ EQUITY      Current liabilities:      Accounts payable $4,261  $4,621 Accrued expenses  7,770   7,937 Deferred revenue  486   408 Operating lease liabilities, current  2,507   2,312 Other current liabilities  18   50 Total current liabilities  15,042   15,328 Operating lease liabilities, net of current portion  21,742   23,652 Other noncurrent liabilities  10   48 Total liabilities  36,794   39,028 Commitments and contingencies      Stockholders’ equity:      Preferred stock, $0.00001 par value; 5,000,000 shares authorized as ofSeptember 30, 2025 and December 31, 2024; zero shares issued and outstanding as of September 30, 2025 and December 31, 2024  —   — Class A common stock, $0.00001 par value; 94,000,000 shares authorizedas of September 30, 2025 and December 31, 2024; 51,759,773 and 55,083,123 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively  1   1 Class B common stock, $0.00001 par value; 6,000,000 shares authorizedas of September 30, 2025 and December 31, 2024; 4,026,571 and 4,044,969 shares issued and outstanding as of September 30, 2025 and December 31,2024, respectively  —   — Additional paid-in capital  721,360   719,804 Accumulated other comprehensive gain  431   136 Accumulated deficit  (449,978)  (392,372)Total stockholders’ equity  271,814   327,569 Total liabilities and stockholders’ equity $308,608  $366,597 

Related News